Sugi Predict

Sugi Predict / Compounds / SCHEMBL29894848

SCHEMBL29894848

SCHEMBL29894848

CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)O

nearest known ligand 0.60

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 10/20 0.60
▸ GCGR P47871 1/20 0.60
▸ GIPR P48546 1/20 0.60
▸ ECE1 P42892 1/20 0.60
▸ MUS81 Q96NY9 1/20 0.60
▸ VIPR2 P41587 5/20 0.58
▸ VIPR1 P32241 3/20 0.58
▸ PTH1R Q03431 1/20 0.57
▸ KISS1R Q969F8 3/20 0.56
▸ CCKBR P32239 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31622727 0.99 GLP1R (0.61) GLP1RGCGRGIPRECE1MUS81
SCHEMBL30763298 0.99 GLP1R (0.61) GLP1RGCGRGIPRECE1MUS81
SCHEMBL31053397 0.99 GLP1R (0.61) GLP1RGCGRGIPRECE1MUS81
SCHEMBL30860128 0.96 GLP1R (0.60) GLP1RGCGRGIPRECE1MUS81
SCHEMBL30860116 0.96 GLP1R (0.60) GLP1RGCGRGIPRECE1MUS81
SCHEMBL31065739 0.96 GLP1R (0.61) GLP1RGCGRGIPRECE1MUS81
SCHEMBL31009219 0.96 GLP1R (0.61) GLP1RGCGRGIPRECE1MUS81
SCHEMBL30860112 0.96 GLP1R (0.61) GLP1RGCGRGIPRECE1MUS81
SCHEMBL31743242 0.95 GLP1R (0.61) GLP1RGCGRGIPRECE1MUS81
SCHEMBL29893853 0.95 GLP1R (0.58) GLP1RGCGRGIPRECE1MUS81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3881861-B1 DOSAGE REGIMES FOR THE ADMINISTRATION OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES ZEALAND PHARMA AS (DK) 2024-07-31 — — EP claimed
CN-118267455-A Formulations of glucagon-like peptide 2 (GLP-2) analogs 西兰制药公司 2024-07-02 — — CN claimed
CN-118055757-A Methods for formulating compositions comprising glucagon-like peptide-2 (GLP-2) analogs 西兰制药公司 2024-05-17 — — CN claimed
EP-3856767-B1 FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES ZEALAND PHARMA AS (DK) 2024-03-27 — — EP claimed
US-20220265551-A1 FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES ZEALAND PHARMA A/S (DK) 2022-08-25 — — US claimed
EP-4398872-B1 PROCESS FOR FORMULATING COMPOSITIONS COMPRISING GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES ZEALAND PHARMA AS (DK) 2025-10-22 — — EP disclosed
EP-4424362-A2 DOSAGE REGIMES FOR THE ADMINISTRATION OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES Zealand Pharma A/S (DK) 2024-09-04 — — EP disclosed
CN-118526577-A Dosage regimen for administration of glucagon-like peptide 2 (GLP-2) analogs 西兰制药公司 2024-08-23 — — CN disclosed
EP-3881861-B1 DOSAGE REGIMES FOR THE ADMINISTRATION OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES ZEALAND PHARMA AS (DK) 2024-07-31 — — EP disclosed
CN-118267455-A Formulations of glucagon-like peptide 2 (GLP-2) analogs 西兰制药公司 2024-07-02 — — CN disclosed
CN-118055757-A Methods for formulating compositions comprising glucagon-like peptide-2 (GLP-2) analogs 西兰制药公司 2024-05-17 — — CN disclosed
US-20240065978-A1 FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES ZEALAND PHARMA A/S (DK) 2024-02-29 — — US disclosed
US-20220265551-A1 FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES ZEALAND PHARMA A/S (DK) 2022-08-25 — — US disclosed
Send feedback